We also focused on the cardiovascular impact of SGLT2 inhibitors in specific subgroups, including patients with T2D, patients with a high risk of ACD, and those diagnosed with ACD, HF, and CKD. This evidence concerns the gene SLC5A2 and granular corneal dystrophy type II.